Clinical trials of insulin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
premixed insulin lispro vs basal-bolus			
Masuda , 2008 n=NA follow-up:	twice-daily 50/50 premixed insulin lispro versus NPH insulin at bedtime and preprandial insulin lispro	insulin-nave type 2 diabetic patients	
morning insulin glargine vs bedtime insulin glargine			
Fritche n=463/232 follow-up: 24 weeks	morning insulin glargine versus bedtime insulin glargine	patients with type 2 diabetes previously treated with oral antidiabetic agents	open
insulin vs control			
UGDP n=414/205 follow-up:	-	-	
UKPDS 33 n=911/896 follow-up:	-	-	
insulin glargine vs control			
ORIGINE , 2012 [NCT00069784] n=6264/6273 follow-up: 6.2 years	insulin glargine (with a target fasting blood glucose level of 95 mg per deciliter versus standard care	with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	
insulin detemir vs glargine			
Fadini , 2011 n=NA	-	-	
insulin glulisine + glargine vs glargine once daily			
Owens , 2011 n=49/57 follow-up: 3 months	basal+bolus (single dose of insulin glulisine immediately prior to the main meal) versus basal insulin (glargin)	patients withT2DM using any basal insulin and HbA1c >7.0% after 3-month of insulin glargine titrated to optimize fasting bloodglucose control	Parallel groups open-label US, UK, Russia
insulin lispro protamine suspension plus lispro vs glargine plus lispro			

continued...

Trial	Treatments	Patients	Trials design and methods
Koivisto , 2011 n=NA	-	-	
repaglinide + insulin vs insulin			
AGEE-1524 [NCT00799448] n=NA follow-up:	repaglinide combined with insulin NPH versus biphasic human insulin 30 alone	type 2 diabetics inadequately controlled with sulfonylurea (SU) +/ biguanide therapy	open Greece
AGEE-3020 n=NA	-	-	
biphasic insulin aspart 30 vs insulin detemir			
Lundby , 2009 n=NA follow-up:	biphasic insulin aspart 30 versus insulin detemir before bedtime	-	
insulin detemir vs NPH insulin			
Hermansen n=236/237 follow-up: 26 weeks	insulin detemir twice-daily versus NPH insulin	insulin-naive people with type 2 diabetes	
lispro insulin vs NPH insulin			
Bastyr , 2000 n=NA follow-up:	insulin lispro versus bedtime NPH insulin	-	
insulin aspart at mealtimes vs NPH insulin once daily			
Gram , 2011 n=NA follow-up:	insulin aspart at mealtimes versus NPH insulin once daily at bedtime	-	
insulin glargine vs placebo			
GRACE - ORIGIN (glargine) , 2012 n=1184 follow-up:	insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter]) versus standard glycemic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan open-label
pioglitazone + insulin vs placebo (add on insulin)			
OPI-502 n=110/112 follow-up: 20 wk	Pioglitazone + insulin versus Placebo + insulin	Insulin-dependent DM-2	Parallel groups
PNFP-014 n=379/187 follow-up: 16 wk	Pioglitazone insulin versus Placebo + insulin	patients with type 2 diabetes	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
insulin glargine plus insulin glulisine vs premixed insulin analogues			
Levin , 2011 n=NA	-	-	
lispro insulin + NPH insulin vs regular insulin + NPH insulin			
Altuntas , 2003 n=NA follow-up:	lispro insulin + NPH insulin versus regular insulin + NPH insulin	-	
lispro twice daily + NPH insulin vs regular insulin + NPH insulin			
Vignati n=NA follow-up:	twice-daily insulin lispro in combination with NPH human insulin versus regular human insulin in combination with NPH human insulin	-	

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at http://www.trialresultscenter.org/go-Q81
- insulin sensitizers - glitazones for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q321
- prevention for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q341
- insulin sensitizer for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q377
- insulin secretagogues for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q409
- prevention for diabetes type 2 in people with impaired glucose tolerance at http://www.trialresultscenter.org/go-Q416
- intensive therapy for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q459
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at http://www.trialresultscenter.org/go-Q513
- insulin therapy for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q548
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at http://www.trialresultscenter.org/go-Q549
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q576
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at http://www.trialresultscenter.org/go-Q692

References

Masuda, 2008:

Masuda H, Sakamoto M, Irie J, Kitaoka A, Shiono K, Inoue G, Atsuda K, Yamada S, Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-nave type 2 diabetic patients. Diabetes Obes Metab 2008;10:1261-5. [18494811] 10.1111/j.1463-1326.2008.00897.x

Fritche , :

Fritsche A, Schweitzer MA, Hring HU Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9 [12809451]

UGDP, :

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982 Nov;31 Suppl 5:1-81 [6757026]

UKPDS 33, :

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12;352:837-53 [9742976]

ORIGINE, 2012:

Gerstein HC, Bosch J, Dagenais GR, Daz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydn LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28 [22686416]

Fadini, 2011:

Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A, Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab 2011;13:718-25. [21410861] 10.1111/j.1463-1326.2011.01396.x

Owens, 2011:

Owens DR, Luzio SD, Sert-Langeron C, Riddle MC Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011;13:1020-7 [21679291] 10.1111/j.1463-1326.2011.01459.x

Koivisto, 2011:

Koivisto V, Cleall S, Pontiroli AE, Giugliano D, Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes Obes Metab 2011;13:1149-57. [21819517] 10.1111/j.1463-1326.2011.01484.x

AGEE-1524, 0:

AGEE-3020, :

Lundby, 2009:

Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Gluud C, Hedetoft C, Jarloev A, Jensen T, Krarup T, Johansen LB, Lund SS, Madsbad S, Mathiesen E, Moelvig J, Nielsen F, Perrild H, Pedersen O, Roeder M, Sneppen SB, Snorgaard Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. Diabetes Obes Metab 2009;11:315-22. [19267709] 10.1111/j.1463-1326.2008.00959.x

Hermansen , :

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74 [16732007] 10.2337/dc05-1365

Bastyr, 2000:

Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE, Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000;23:1236-41. [10977012]

Gram, 2011:

Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, Yderstrde K, Gjessing H, Hansen HM, Vestergaard V, Hangaard J, Beck-Nielsen H, Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 2011;34:27-33. [20929990] 10.2337/dc10-0531

GRACE - ORIGIN (glargine), 2012:

OPI-502, :

PNFP-014, :

Levin, 2011:

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R, Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin Ther 2011;33:841-50. [21719107] 10.1016/j.clinthera.2011.05.091

Altuntas, 2003:

Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, Karul S, Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes Obes Metab 2003;5:371-8. [14617222]

Vignati, 0:

Vignati L, Anderson JH, Iversen PW, Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther ;19:1408-21. [9444449]

2 impaired fasting glucose

Trial	Treatments	Patients	Trials design and methods
insulin glargine vs placebo			
GRACE - ORIGIN (glargine) , 2012 n=1184 follow-up:	insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter]) versus standard glycemic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan open-label

More details and results :

- prevention for impaired fasting glucose in all type of patients at http://www.trialresultscenter.org/go-Q342

References

GRACE - ORIGIN (glargine), 2012:

Entry terms: pioglitazone, Actos